Navigation Links
Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
Date:8/7/2008

RALEIGH, N.C., Aug. 7 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that Nader Naeymi-Rad has been appointed Chief Operating Officer. His former role at Campbell Alliance of Senior Vice President and head of the firm's Brand Management Practice will be assumed by Darius Naigamwalla under the same title.

This new senior executive management role for Mr. Naeymi-Rad follows an 11-year tenure at Campbell Alliance extending from the original founding of the firm in 1997 by CEO John Campbell. In fact, Mr. Naeymi-Rad was the first employee that Mr. Campbell hired upon founding the firm.

"My relationship with Nader dates back more than 14 years to when we first worked together at Glaxo [now GlaxoSmithKline]. I have depended on him as my friend and trusted business advisor since that time. I'm proud to appoint him to this new senior executive management role in which he can continue to build upon his long-standing track record of success here at Campbell Alliance," stated Mr. Campbell.

Since joining Campbell Alliance, Mr. Naeymi-Rad has played a pivotal role in the growth of the firm and, specifically, the Brand Management Practice. He has worked on more than 500 client projects with pharmaceutical and biotech companies in a dozen countries across North America, the United Kingdom, Europe, and Asia. He has led the development of the Brand Management Practice from its inception to its present state. The practice currently has more than 80 consulting professionals around the world, and under Mr. Naeymi-Rad's leadership, it has maintained at least 35% year-over-year revenue growth since its inception. Mr. Naeymi-Rad also led the development of new service offerings including the Brand Management Practice's Launch Playbook(TM) (launch planning and execution) and Innovation2Value(TM) (commercial planning) capabilities. In addition, he helped launch and co-lead the firm's Business Development Practice and spearheaded the development of the firm's operations in the United Kingdom and Europe.

In his new role as Chief Operating Officer, Mr. Naeymi-Rad will oversee all business operations of the six consulting practice areas at Campbell Alliance and work to refine core business processes and improve operational alignment among the practice areas. These efforts will include enhancing methods and tools, identifying and shaping new service offerings and new potential practice areas, and leading the firm's next generation approach to account management.

"I'm proud to say that our business has demonstrated a consistently aggressive growth pace while maintaining stellar client satisfaction. I'm looking forward to the challenge of taking on this new role and helping the firm to further differentiate its offerings and continue its expansion into both new practice areas and geographic areas," stated Mr. Naeymi-Rad.

Mr. Naeymi-Rad has been published in numerous industry journals and is a frequent speaker at industry conferences, having served in a chairperson role on many occasions, covering topics related to developing and implementing commercial strategies and improving commercial processes.

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com .

CONTACT:

James Forte

Director, Public and Media Relations

Campbell Alliance

+1 919 844 7100, extension 7195

jforte@campbellalliance.com


'/>"/>
SOURCE Campbell Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
3. John Marshall and Kevin McGuinness Appointed to Ellex Board
4. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
5. David Mott Appointed Non Executive Director at Shire
6. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
7. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
8. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
9. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
10. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
11. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Savannah River Remediation LLC group ... NewTechBio,s NT-MAX Lake & Pond Sludge and ... in conjunction with Hexa Armor/ Rhombo cover manufactured ... Pollutant Discharge Elimination System requirements. The ... history of elevated pH levels, above 8.5, especially ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented today ... clinical trial for its lead drug candidate, AC0010, at the World Conference on ... to determine the safety, antitumor activity, and recommended phase II dosage of AC0010 ...
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication Process (Extrusion, Injection ... to 2026", published by MarketsandMarkets, the global market size was USD 645.4 Million ... an of CAGR of 6.2% between 2016 and 2026. ... ... , , ...
Breaking Biology Technology:
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ... Systems) ... largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of an ...
Breaking Biology News(10 mins):